Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in Hemodialysis

American Journal of Kidney Diseases

Volumn 52, Issue 4, 2008, Pages 727-736

  Streja, Elani ^a,b   Kovesdy, Csaba P ^c   Greenland, Sander ^b   Kopple, Joel D ^a,b,d   McAllister, Charles J ^e   Nissenson, Allen R ^d   Kalantar Zadeh, Kamyar ^a,b,d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DAVITA INC   (United States)

Author keywords

Anemia; erythropoiesis stimulating agent; hemodialysis population; iron stores; malnutrition inflammation cachexia syndrome (MICS); thrombocytosis

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CASE MIX; DATA BASE; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEPLETION; IRON STORAGE; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOCYTOSIS;

EID: 52049121838     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.05.029     Document Type: Article

References (41)

1. Van Wyck D.B., Bailie G., and Aronoff G. Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 39 (2002) 426-432
2. Locatelli F., Pisoni R.L., Akizawa T., et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 44 (2004) 27-33
3. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
4. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S146-S146
5. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
6. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
7. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
8. Phrommintikul A., Haas S.J., Elsik M., and Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369 (2007) 381-388
9. Strippoli G.F., Tognoni G., Navaneethan S.D., Nicolucci A., and Craig J.C. Haemoglobin targets: We were wrong, time to move on. Lancet 369 (2007) 346-350
10. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., Liu E., and Kopple J.D. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 43 (2004) 671-684
11. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Michael B., and Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
12. Coyne D. Challenging the boundaries of anemia management: A balanced approach to i.v. iron and EPO therapy. Kidney Int Suppl 101 (2006) S1-S3
13. Kadikoylu G., Yavasoglu I., Bolaman Z., and Senturk T. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc 98 (2006) 398-402
14. Gurbel P.A. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: Emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 7 suppl 4 (2006) S20-S28
15. Aljaroudi W.A., Halabi A.R., and Harrington R.A. Platelet inhibitor therapy for patients with cardiovascular disease: Looking toward the future. Curr Hematol Rep 4 (2005) 397-404
16. Kalantar-Zadeh K., Kilpatrick R.D., McAllister C.J., Greenland S., and Kopple J.D. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: The 58th annual fall conference and scientific sessions. Hypertension 45 (2005) 811-817
17. Kovesdy C.P., Trivedi B.K., Kalantar-Zadeh K., and Anderson J.E. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 69 (2006) 560-564
18. Barany P., Divino Filho J.C., and Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29 (1997) 565-568
19. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., Lee G.H., Nissenson A.R., and Kopple J.D. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
20. Gunnell J., Yeun J.Y., Depner T.A., and Kaysen G.A. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
21. Longenecker J.C., Coresh J., Klag M.J., et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE Study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 11 (2000) 520-529
22. Kalantar-Zadeh K., Kopple J.D., Kilpatrick R.D., et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 46 (2005) 489-500
23. Kalantar-Zadeh K., Kilpatrick R.D., Kuwae N., et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 20 (2005) 1880-1889
24. Nather A., Mayerhofer K., Grimm C., et al. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy. Anticancer Res 23 (2003) 2991-2994
25. Hefler L., Mayerhofer K., Leibman B., et al. Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol 21 (2000) 309-314
26. Valentini G., Chianese U., Tirri G., and Giordano M. Thrombocytosis in progressive generalized sclerosis (scleroderma) and in other rheumatic diseases. Z Rheumatol 37 (1978) 233-241
27. Rodriguez G.C., Clarke-Pearson D.L., Soper J.T., Berchuck A., Synan I., and Dodge R.K. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 83 (1994) 445-448
28. Sokunbi D.O., Wadhwa N.K., and Suh H. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis. Adv Perit Dial 10 (1994) 77-80
29. Dominguez I., Crippa S., Thayer S.P., et al. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. Ann Surg 247 (2008) 571-579
30. Gross S., Keefer V., and Newman A.J. The platelets in iron-deficiency anemia. I. The response to oral and parenteral iron. Pediatrics 34 (1964) 315-323
31. Dahl N.V., Henry D.H., and Coyne D.W. Thrombosis with erythropoietic stimulating agents-Does iron-deficient erythropoiesis play a role?. Semin Dial 21 (2008) 210-211
32. Franchini M. Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. Hematology 8 (2003) 259-262
33. Tekin D., Yavuzer S., Tekin M., Akar N., and Cin S. Possible effects of antioxidant status on increased platelet aggregation in childhood iron-deficiency anemia. Pediatr Int 43 (2001) 74-77
34. Kurekci A.E., Atay A.A., Sarici S.U., Zeybek C., Koseoglu V., and Ozcan O. Effect of iron therapy on the whole blood platelet aggregation in infants with iron deficiency anemia. Thromb Res 97 (2000) 281-285
35. Sidi Y., Douer D., Krugliac J., and Pinkhas J. Platelet aggregation and adhesiveness in severe iron deficiency due to menorrhage. New Istanbul Contrib Clin Sci 12 (1978) 161-165
36. Youdim M.B., Woods H.F., Mitchell B., Grahame-Smith D.G., and Callender S. Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin Sci Mol Med 48 (1975) 289-295
37. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
38. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (1989) 992-1000
39. Beguin Y., Loo M., R'Zik S., et al. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: Correlation of platelet count with erythropoietic activity and iron parameters. Eur J Haematol 53 (1994) 265-270
40. Loo M., and Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 93 (1999) 3286-3293
41. Murray M.J., Murray A.B., Murray M.B., and Murray C.J. The adverse effect of iron repletion on the course of certain infections. Br Med J 2 (1978) 1113-1115